0001209191-23-047384.txt : 20230825
0001209191-23-047384.hdr.sgml : 20230825
20230825173050
ACCESSION NUMBER: 0001209191-23-047384
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230823
FILED AS OF DATE: 20230825
DATE AS OF CHANGE: 20230825
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dupont Jakob
CENTRAL INDEX KEY: 0001553335
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40881
FILM NUMBER: 231209444
MAIL ADDRESS:
STREET 1: C/O ONCOMED PHARMACEUTICALS, INC.
STREET 2: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pyxis Oncology, Inc.
CENTRAL INDEX KEY: 0001782223
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831160910
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 HARRISON AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02118
BUSINESS PHONE: (617) 221-9059
MAIL ADDRESS:
STREET 1: 321 HARRISON AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02118
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-23
0
0001782223
Pyxis Oncology, Inc.
PYXS
0001553335
Dupont Jakob
C/O PYXIS ONCOLOGY, INC.
321 HARRISON AVENUE
BOSTON
MA
02118
1
0
0
0
0
Stock Option (Right to buy)
26.61
2023-08-23
4
A
0
5879
A
2030-09-01
Common Stock
5879
5879
D
Stock Option (Right to buy)
26.61
2023-08-23
4
A
0
3534
A
2031-02-12
Common Stock
3534
3534
D
Stock Option (Right to buy)
15.37
2023-08-23
4
A
0
17250
A
2032-09-29
Common Stock
17250
17250
D
The shares subject to this option vested in full immediately prior to the closing of the merger described in footnote 2.
On May 23, 2023, the Issuer, Ascent Merger Sub Corp., a wholly-owned subsidiary of the Issuer, or the Merger Sub, and Apexigen, Inc., or Apexigen, entered into a definitive agreement for the Issuer to acquire Apexigen, or the Merger Agreement. Under the terms of the Merger Agreement, the reporting person's options to purchase shares of Apexigen Common Stock, or the Apexigen Options, that were outstanding immediately prior to the effective time of the merger were assumed by the Issuer and converted into options to acquire, on substantially similar terms and conditions, the number of shares of the Issuer Common Stock determined by multiplying the number of shares subject to the Apexigen Options by 0.1725, or the Exchange Ratio, shares of the Issuer Common Stock, rounded down to the nearest whole share, with an exercise price per share equal to the exercise price per share of such Apexigen Option divided by the Exchange Ratio, rounded up to the nearest whole cent.
/s/ Pamela Connealy, Attorney-in-Fact for Jakob Dupont
2023-08-25